Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies targeting immune dysregulation, with a focus on inflammatory diseases. Its lead product candidate, AVTX-009, is a humanized anti-IL-1β monoclonal antibody aimed at treating conditions like hidradenitis suppurativa. Avalo operates through clinical development, relying on third-party manufacturing and regulatory approvals, targeting global markets in dermatology, gastroenterology, and rheumatology with a focus on innovative biologic therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.